1887
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.

Tuberculosis of the Liver, Biliary Tract, and Pancreas

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.
Buy this Microbiology Spectrum Article
Price Non-Member $15.00
  • Authors: G. Shelton McMullan1, James H. Lewis2
  • Editor: David Schlossberg3
  • VIEW AFFILIATIONS HIDE AFFILIATIONS
    Affiliations: 1: Division of Gastroenterology, Georgetown University Hospital, Washington, DC 20007; 2: Division of Hepatology, Department of Medicine, Georgetown University Hospital, Washington, DC 20007; 3: Philadelphia Health Department, Philadelphia, PA
  • Source: microbiolspec February 2017 vol. 5 no. 1 doi:10.1128/microbiolspec.TNMI7-0025-2016
  • Received 01 November 2016 Accepted 10 January 2017 Published 24 February 2017
  • G. Shelton McMullan, g.s.mcmullan@gunet.georgetown.edu
image of Tuberculosis of the Liver, Biliary Tract, and Pancreas
    Preview this microbiology spectrum article:
    Zoom in
    Zoomout

    Tuberculosis of the Liver, Biliary Tract, and Pancreas, Page 1 of 2

    | /docserver/preview/fulltext/microbiolspec/5/1/TNMI7-0025-2016-1.gif /docserver/preview/fulltext/microbiolspec/5/1/TNMI7-0025-2016-2.gif
  • Abstract:

    Tuberculosis of the liver, biliary tract, and pancreas is discussed. In addition, tuberculosis in the setting of HIV-AIDS and liver transplantation is explored. Drug-induced liver injury secondary to antituberculosis medication and monitoring and prophylactic treatment for such injury is also considered.

  • Citation: McMullan G, Lewis J. 2017. Tuberculosis of the Liver, Biliary Tract, and Pancreas. Microbiol Spectrum 5(1):TNMI7-0025-2016. doi:10.1128/microbiolspec.TNMI7-0025-2016.

References

1. Ullom JT. 1909. The liver in tuberculosis. Am J Med Sci 137:694–699.
2. Bristowe JS. 1858. On the connection between abscess of the liver and gastrointestinal ulceration. Trans Pathol Soc London 9:241–252.
3. Chien RN, Lin PY, Liaw YF. 1995. Hepatic tuberculosis: comparison of miliary and local form. Infection 23:5–8. [PubMed]
4. Rolleston HD. 1905. Disease of the Liver, Gallbladder and Bile Ducts, p 336–346. WB Saunders, Philadelphia, PA.
5. Saphir O. 1929. Changes in the liver and pancreas in chronic tuberculosis. Arch Pathol 7:1025–1039.
6. Torrey RG. 1916. The occurrence of miliary tuberculosis of the liver in the course of pulmonary tuberculosis. Am J Med Sci 151:549–556.
7. Gillman T, Gillman J. 1945. Modified liver aspiration biopsy apparatus and technique, with special reference to its clinical applications as assessed by 500 biopsies. S Afr J Med Sci 10:53–66.
8. Finckh ES, Baker SJ, Ryan MMP. 1953. The value of liver biopsy in the diagnosis of tuberculosis and sarcoidosis. Med J Aust 2:369–374. [PubMed]
9. Klatskin G, Yesner R. 1950. Hepatic manifestations of sarcoidosis and other granulomatous diseases; a study based on histological examination of tissue obtained by needle biopsy of the liver. Yale J Biol Med 23:207–248. [PubMed]
10. Mansuy MM, Seiferth WJ. 1950. Miliary tuberculosis of the liver: liver biopsy as an adjunct to diagnosis. Am J Med Sci 220:293–297. [PubMed]
11. Gold J, Wigderson A, Lehman E, Schwartz IR. 1957. Tuberculous hepatitis; report of a case with review of the literature. Gastroenterology 33:113–120. [PubMed]
12. Gulati PD, Vyas PB. 1965. Tuberculosis of the liver. J Indian Med Assoc 45:144–145. [PubMed]
13. Alvarez SZ, Carpio R. 1983. Hepatobiliary tuberculosis. Dig Dis Sci 28:193–200. [PubMed]
14. Bernhard JS, Bhatia G, Knauer CM. 2000. Gastrointestinal tuberculosis: an eighteen-patient experience and review. J Clin Gastroenterol 30:397–402. [PubMed]
15. Essop AR, Posen JA, Hodkinson JH, Segal I. 1984. Tuberculosis hepatitis: a clinical review of 96 cases. Q J Med 53:465–477. [PubMed]
16. Maharaj B, Leary WP, Pudifin DJ. 1987. A prospective study of hepatic tuberculosis in 41 black patients. Q J Med 63:517–522. [PubMed]
17. Oliva A, Duarte B, Jonasson O, Nadimpalli V. 1990. The nodular form of local hepatic tuberculosis. A review. J Clin Gastroenterol 12:166–173. [PubMed]
18. Snider GL. 1997. Tuberculosis then and now: a personal perspective on the last 50 years. Ann Intern Med 126:237–243. [PubMed]
19. Chaisson RE, Slutkin G. 1989. Tuberculosis and human immunodeficiency virus infection. J Infect Dis 159:96–100. [PubMed]
20. Small PM, Schecter GF, Goodman PC, Sande MA, Chaisson RE, Hopewell PC. 1991. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 324:289–294. [PubMed]
21. Yang Z, Kong Y, Wilson F, Foxman B, Fowler AH, Marrs CF, Cave MD, Bates JH. 2004. Identification of risk factors for extrapulmonary tuberculosis. Clin Infect Dis 38:199–205. [PubMed]
22. Horsburgh CR, Jr. 1991. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med 324:1332–1338. [PubMed]
23. Inderlied CB, Kemper CA, Bermudez LE. 1993. The Mycobacterium avium complex. Clin Microbiol Rev 6:266–310. [PubMed]
24. Jacques J, Sloan JM. 1970. The changing pattern of miliary tuberculosis. Thorax 25:237–240. [PubMed]
25. Munt PW. 1972. Miliary tuberculosis in the chemotherapy era: with a clinical review in 69 American adults. Medicine (Baltimore) 51:139–155. [PubMed]
26. Dourakis SP, Saramadou R, Alexopoulou A, Kafiri G, Deutsch M, Koskinas J, Archimandritis AJ. 2007. Hepatic granulomas: a 6-year experience in a single center in Greece. Eur J Gastroenterol Hepatol 19:101–104. [PubMed]
27. Drebber U, Kasper HU, Ratering J, Wedemeyer I, Schirmacher P, Dienes HP, Odenthal M. 2008. Hepatic granulomas: histological and molecular pathological approach to differential diagnosis—a study of 442 cases. Liver Int 28:828–834. [PubMed]
28. Mather G, Dawson J, Hoyle C. 1955. Liver biopsy in sarcoidosis. Q J Med 24:331–350. [PubMed]
29. Korn RJ, Kellow WF, Heller P, Chomet B, Zimmerman HJ. 1959. Hepatic involvement in extrapulmonary tuberculosis; histologic and functional characteristics. Am J Med 27:60–71. [PubMed]
30. Alexander JF, Galambos JT. 1973. Granulomatous hepatitis. The usefulness of liver biopsy in the diagnosis of tuberculosis and sarcoidosis. Am J Gastroenterol 59:23–30. [PubMed]
31. Haex AJC, Van Beek C. 1955. Tuberculosis and Aspiration Liver Biopsy. Bohn, Haarlem, The Netherlands.
32. Yamaguchi BT, Braunstein H. 1965. Fluorescent stain for tubercle bacilli in histological sections. II. Diagnostic efficiency in granulomatous lesions of the liver. Am J Clin Pathol 43:184–187.
33. Okuda K, Kimura K, Takara K, Ohto M, Omata M, Lesmana L. 1986. Resolution of diffuse granulomatous fibrosis of the liver with antituberculous chemotherapy. Gastroenterology 91:456–460.
34. Small MJ. 1974. Tuberculosis of the liver: scan appearance before and after successful treatment. J Nucl Med 15:135–136. [PubMed]
35. Zipser RD, Rau JE, Ricketts RR, Bevans LC. 1976. Tuberculous pseudotumors of the liver. Am J Med 61:946–951. [PubMed]
36. Greene JB, Sidhu GS, Lewin S, Levine JF, Masur H, Simberkoff MS, Nicholas P, Good RC, Zolla-Pazner SB, Pollock AA, Tapper ML, Holzman RS. 1982. Mycobacterium avium-intracellulare: a cause of disseminated life-threatening infection in homosexuals and drug abusers. Ann Intern Med 97:539–546. [PubMed]
37. Lewis JH. 2007. Hepatic granulomas, p 1425–1448. In Schiff ER, Sorrell MF, Maddrey WC (ed), Schiff’s Diseases of the Liver, 10th ed. Lippincott, Williams and Wilkins, Baltimore, MD.
38. Davis JM, Ramakrishnan L. 2008. “The very pulse of the machine”: the tuberculous granuloma in motion. Immunity 28:146–148. [PubMed]
39. Egen JG, Rothfuchs AG, Feng CG, Winter N, Sher A, Germain RN. 2008. Macrophage and T cell dynamics during the development and disintegration of mycobacterial granulomas. Immunity 28:271–284. [PubMed]
40. Bowry S, Chan CH, Weiss H, Katz S, Zimmerman HJ. 1970. Hepatic involvement in pulmonary tuberculosis. Histologic and functional characteristics. Am Rev Respir Dis 101:941–948. [PubMed]
41. Buckingham WB, Turner GC, Knapp WB, Young QD, Schaffner F. 1956. Liver biopsy in a tuberculosis hospital. Dis Chest 29:675–683. [PubMed]
42. Sabharwal BD, Malhotra N, Garg R, Malhotra V. 1995. Granulomatous hepatitis: a retrospective study. Indian J Pathol Microbiol 38:413–416. [PubMed]
43. Sartin JS, Walker RC. 1991. Granulomatous hepatitis: a retrospective review of 88 cases at the Mayo Clinic. Mayo Clin Proc 66:914–918. [PubMed]
44. Rudzki C, Ishak KG, Zimmerman HJ. 1975. Chronic intrahepatic cholestasis of sarcoidosis. Am J Med 59:373–387. [PubMed]
45. McCullough NB, Eisele CW. 1951. Brucella hepatitis leading to cirrhosis of the liver. AMA Arch Intern Med 88:793–802. [PubMed]
46. Essop AR, Posen JA, Savitch I, Levin J, Kew MC. 1984. Radiocolloid liver imaging in tuberculous hepatitis. Clin Nucl Med 9:81–84. [PubMed]
47. Jones K, Peck WM. 1944. Incidence of fatty liver in tuberculosis with special reference to tuberculosis enteritis. Arch Intern Med (Chicago) 74:371–374.
48. Fernández Pintos J, Cabo Rey L, Souto Boo J, Llopis Rey J. 1972. Tuberculosis miliar hepática combinada con una proliferación de hepatocitos gigantes. Rev Esp Enferm Apar Dig 38:847–854. [PubMed]
49. Sherlock S. 1981. Diseases of the Liver and Biliary System, 6th ed, p 395. Blackwell Scientific, Oxford, United Kingdom.
50. Seife M, Kessler BJ, Hoffman J, Lisa JR. 1951. A clinical, functional, and needle biopsy study of the liver in pulmonary tuberculosis. Am Rev Tuberc 63:202–209. [PubMed]
51. Ban B. 1955. Hepatic damage in chronic pulmonary tuberculosis. Am Rev Tuberc 72:71–90. [PubMed]
52. Steidl J, Heise FJ. 1933. Studies of liver function in advanced pulmonary tuberculosis. Am J Med Sci 186:631–640.
53. Ishak KG, Zimmerman HJ. 1988. Drug-induced and toxic granulomatous hepatitis. Baillieres Clin Gastroenterol 2:463–480. [PubMed]
54. Valdez VA, Herrera NE. 1978. Granulomatous hepatitis: spectrum of scintigraphic manifestations. Clin Nucl Med 3:393–396. [PubMed]
55. Harrington PT, Gutiérrez JJ, Ramirez-Ronda CH, Quiñones-Soto R, Bermúdez RH, Chaffey J. 1982. Granulomatous hepatitis. Rev Infect Dis 4:638–655. [PubMed]
56. Vilaichone RK, Vilaichone W, Tumwasorn S, Suwanagool P, Wilde H, Mahachai V. 2003. Clinical spectrum of hepatic tuberculosis: comparison between immunocompetent and immunocompromised hosts. J Med Assoc Thai 86(Suppl 2):S432–S438. [PubMed]
57. Schaffner F, Turner GC, Eshbaugh DE, Buckingham WB, Popper H. 1953. Hypergammaglobulinemia in pulmonary tuberculosis. AMA Arch Intern Med 92:490–493. [PubMed]
58. Hersch C. 1964. Tuberculosis of the liver: a study of 200 cases. S Afr Med J 38:857–863. [PubMed]
59. Guckian JC, Perry JE. 1966. Granulomatous hepatitis. An analysis of 63 cases and review of the literature. Ann Intern Med 65:1081–1100. [PubMed]
60. Arrese M, Lopez F, Rossi R, Traipe E, Cruz F. 1997. Extrahepatic cholestasis attributable to tuberculous adenitis. Am J Gastroenterol 92:912–913. [PubMed]
61. Pineda FM, Dalmacio-Cruz A. 1966. Tuberculosis of the liver and the porta hepatis. Report of 9 cases. Acta Med Philipp 2:128–139. [PubMed]
62. Simon HB, Wolff SM. 1973. Granulomatous hepatitis and prolonged fever of unknown origin: a study of 13 patients. Medicine (Baltimore) 52:1–21. [PubMed]
63. Tahiliani RR, Parikh JA, Hegde AV, Bhatia SJ, Deodhar KP, Kapadia NM, Khokhani RC, Damle VB. 1983. Hepatic tuberculosis simulating hepatic amoebiasis. J Assoc Physicians India 31:679–680. [PubMed]
64. Essop AR, Segal I, Posen J, Noormohamed N. 1983. Tuberculous abscess of the liver. A case report. S Afr Med J 63:825–826. [PubMed]
65. Rahmatulla RH, al-Mofleh IA, al-Rashed RS, al-Hedaithy MA, Mayet IY. 2001. Tuberculous liver abscess: a case report and review of literature. Eur J Gastroenterol Hepatol 13:437–440. [PubMed]
66. Debray J, Krulik M, Bernard JF. 1972. La tuberculose pseudo-tumorale du foie. A propos d’une observation personnelle. Sem Hop 48:3165–3173. [PubMed]
67. Fernandes JD, Nebesar RA, Wall SG, Minihan PT. 1984. Report of tuberculous hepatitis presenting as metastatic disease. Clin Nucl Med 9:345–347. [PubMed]
68. Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang CH, Chang FY, Lee SD. 2003. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 37:924–930. [PubMed]
69. Hulnick DH, Megibow AJ, Naidich DP, Hilton S, Cho KC, Balthazar EJ. 1985. Abdominal tuberculosis: CT evaluation. Radiology 157:199–204. [PubMed]
70. Kok KY, Yapp SK. 1999. Isolated hepatic tuberculosis: report of five cases and review of the literature. J Hepatobiliary Pancreat Surg 6:195–198. [PubMed]
71. Petera V, Vesely V, Kulich V, Dura J. 1972. The clinical and morphological correlations in the Au/SH antigen carriers. Digestion 5:227–228.
72. Procházka M, Vyhnánek F, Vorreith V, Jirásek M. 1986. Bleeding into solitary hepatic tuberculoma. Report of a case treated by resection. Acta Chir Scand 152:73–75. [PubMed]
73. Sanai FM, Ashraf S, Abdo AA, Satti MB, Batwa F, Al-Husseini H, Saleh AM, Bzeizi KI. 2008. Hepatic granuloma: decreasing trend in a high-incidence area. Liver Int 28:1402–1407. [PubMed]
74. Palmer KR, Patil DH, Basran GS, Riordan JF, Silk DB. 1985. Abdominal tuberculosis in urban Britain—a common disease. Gut 26:1296–1305. [PubMed]
75. Terry RB, Gunnar RM. 1957. Primary miliary tuberculosis of the liver. J Am Med Assoc 164:150–157. [PubMed]
76. Cleve EA, Gibson JR, Webb WM. 1954. Atypical tuberculosis of the liver with jaundice. Ann Intern Med 41:251–260. [PubMed]
77. Cinque TJ, Gary NE, Palladino VS. 1964. “Primary” miliary tuberculosis of the liver. Am J Gastroenterol 42:611–619. [PubMed]
78. Amarapurkar DN, Patel ND, Amarapurkar AD. 2008. Hepatobiliary tuberculosis in western India. Indian J Pathol Microbiol 51:175–181. [PubMed]
79. al Karawi MA, Mohamed AE, Yasawy MI, Graham DY, Shariq S, Ahmed AM, al Jumah A, Ghandour Z. 1995. Protean manifestation of gastrointestinal tuberculosis: report on 130 patients. J Clin Gastroenterol 20:225–232. [PubMed]
80. Lundstedt C, Nyman R, Brismar J, Hugosson C, Kagevi I. 1996. Imaging of tuberculosis. II. Abdominal manifestations in 112 patients. Acta Radiol 37(3P2):489–495. [PubMed]
81. Huang WT, Wang CC, Chen WJ, Cheng YF, Eng HL. 2003. The nodular form of hepatic tuberculosis: a review with five additional new cases. J Clin Pathol 56:835–839. [PubMed]
82. Herman P, Pugliese V, Laurino Neto R, Machado MC, Pinotti HW. 1995. Nodular form of local hepatic tuberculosis: case report. J Trop Med Hyg 98:141–142. [PubMed]
83. Leader SA. 1952. Tuberculosis of the liver and gall-bladder with abscess formation: a review and case report. Ann Intern Med 37:594–606. [PubMed]
84. Rab SM, Beg MZ. 1977. Tuberculous liver abscess. Br J Clin Pract 31:157–158. [PubMed]
85. Spiegel CT, Tuazon CU. 1984. Tuberculous liver abscess. Tubercle 65:127–131. [PubMed]
86. Wee A, Nilsson B, Wang TL, Yap I, Siew PY. 1995. Tuberculous pseudotumor causing biliary obstruction. Report of a case with diagnosis by fine needle aspiration biopsy and bile cytology. Acta Cytol 39:559–562. [PubMed]
87. Wissmer B. 1976. Tuberculosis of the liver, p 511–514. In Bockus HL (ed), Gastroenterology, vol 3. WB Saunders, Philadelphia, PA.
88. Dwek JH, Schechter LS, Grinberg ME. 1981. Hepatic angiography in a patient with tuberculosis of the liver. Am J Gastroenterol 75:307–308. [PubMed]
89. Bhargava SP, Sharma ML. 1962. Multiple tuberculoma of liver. A case report. J Indian Med Assoc 38:552–554. [PubMed]
90. Duckworth WC. 1964. Tuberculosis of the liver. S Afr Med J 38:945. [PubMed]
91. Bhargava DK, Verma K, Malaviya AN. 1983. Solitary tuberculoma of liver: laparoscopic, histologic, and cytologic diagnosis. Gastrointest Endosc 29:329–330.
92. Treska V, Hes O, Nemcova J. 2009. Liver tuberculoma. Bratisl Lek Listy (Tlacene Vyd) 110:363–365. [PubMed]
93. Brauner M, Buffard MD, Jeantils V, Legrand I, Gotheil C. 1989. Sonography and computed tomography of macroscopic tuberculosis of the liver. J Clin Ultrasound 17:563–568. [PubMed]
94. Moskovic E. 1990. Macronodular hepatic tuberculosis in a child: computed tomographic appearances. Br J Radiol 63:656–658. [PubMed]
95. Nagai H, Shimizu S, Kawamoto H, Yamanoue M, Tsuchiya T, Yamamoto M. 1989. A case of solitary tuberculosis of the liver. Jpn J Med 28:251–255. [PubMed]
96. Levine B, Chaisson RE. 1991. Mycobacterium kansasii: a cause of treatable pulmonary disease associated with advanced human immunodeficiency virus (HIV) infection. Ann Intern Med 114:861–868. [PubMed]
97. Murata Y, Yamada I, Sumiya Y, Shichijo Y, Suzuki Y. 1996. Abdominal macronodular tuberculomas: MR findings. J Comput Assist Tomogr 20:643–646. [PubMed]
98. Kawamori Y, Matsui O, Kitagawa K, Kadoya M, Takashima T, Yamahana T. 1992. Macronodular tuberculoma of the liver: CT and MR findings. Am J Roentgenol 158:311–313. [PubMed]
99. Asada Y, Hayashi T, Sumiyoshi A, Aburaya M, Shishime E. 1991. Miliary tuberculosis presenting as fever and jaundice with hepatic failure. Hum Pathol 22:92–94. [PubMed]
100. Kohen MD, Altman KA. 1973. Jaundice due to a rare cause: tuberculous lymphadenitis. Am J Gastroenterol 59:48–53. [PubMed]
101. Proudfoot AT, Akhtar AJ, Douglas AC, Horne NW. 1969. Miliary tuberculosis in adults. BMJ 2:273–276. [PubMed]
102. Shan SA, Neff TA. 1974. Miliary tuberculosis. Am J Med 56:494–505. [PubMed]
103. Hickey A, Gounder L, Moosa MY, Drain PK. 2015. A systematic review of hepatic tuberculosis with considerations in HIV co-infection. BMC Infect Dis 15:209. [PubMed]
104. Curry FJ, Alcott D. 1955. Tuberculous hepatitis with jaundice; report of two cases. Gastroenterology 28:1037–1042. [PubMed]
105. Godwin JE, Coleman AA, Sahn SA. 1991. Miliary tuberculosis presenting as hepatic and renal failure. Chest 99:752–754. [PubMed]
106. Hussain W, Mutimer D, Harrison R, Hubscher S, Neuberger J. 1995. Fulminant hepatic failure caused by tuberculosis. Gut 36:792–794. [PubMed]
107. Toptas T, Ilhan B, Bilgin H, Dincses E, Ozdogan O, Kaygusuz-Atagunduz I, Odabasi Z, Korten V, Firatli-Tuglular T. 2015. Miliary tuberculosis induced acute liver failure. Case Rep Infect Dis 2015:759341. [PubMed]
108. Airede KI. 1990. Congenital miliary tuberculosis. Ann Trop Paediatr 10:363–368. [PubMed]
109. Berk DR, Sylvester KG. 2004. Congenital tuberculosis presenting as progressive liver dysfunction. Pediatr Infect Dis J 23:78–80. [PubMed]
110. Chen HJ, Chiu NC, Kao HA, Wang TY. 2004. Perinatal tuberculosis in a three-month-old infant. J Formos Med Assoc 103:144–147. [PubMed]
111. Chou YH. 2002. Congenital tuberculosis proven by percutaneous liver biopsy: report of a case. J Perinat Med 30:423–425. [PubMed]
112. Debre R, Furiet-Laforet M, Royer P. 1948. Congenital transplacental tuberculosis of icteric form. Arch Fr Pediatr 5:225–231.
113. Tobias H, Sherman A. 2002. Hepatobiliary tuberculosis, p 537–547. In Rom WN, Garay SM (ed), Tuberculosis, 2nd ed. Lippincott Williams & Wilkins, Philadelphia, PA.
114. Cantwell MF, Shehab ZM, Costello AM, Sands L, Green WF, Ewing EP, Jr, Valway SE, Onorato IM. 1994. Brief report: congenital tuberculosis. N Engl J Med 330:1051–1054. [PubMed]
115. Emiralioglu N, Dogru D, Oguz B, Yalcin E, Ozcelik U, Konuskan B, Cengiz AB, Kiper N. 2016. Congenital tuberculosis after in-vitro fertilization in a woman previously undiagnosed with tuberculosis salpingitis. Pediatr Neonatol 57:539–540. [PubMed]
116. McNutt DR, Fudenberg HH. 1971. Disseminated scotochromogen infection and unusual myeloproliferative disorder. Report of a case and review of the literature. Ann Intern Med 75:737–744. [PubMed]
117. Stewart C, Jackson L. 1976. Spleno-hepatic tuberculosis due to Mycobacterium kansasii. Med J Aust 2:99–101. [PubMed]
118. Smith ER, Penman HG. 1971. Histological diagnosis of M. kansasii lung infection: a case report. Pathology 3:93–98. [PubMed]
119. Hsieh SM, Hung CC, Chen MY, Hsueh PR, Chang SC, Luh KT. 1999. The role of tissue studies in facilitating early initiation of antimycobacterial treatment in AIDS patients with disseminated mycobacterial disease. Int J Tuberc Lung Dis 3:521–527. [PubMed]
120. Shah SR, Rastegar DA, Nicol TL. 2000. Case report. Diagnosis of disseminated Mycobacterium avium complex infection by liver biopsy. AIDS Read 10:669–672. [PubMed]
121. Patel KM. 1981. Granulomatous hepatitis due to Mycobacterium scrofulaceum: report of a case. Gastroenterology 81:156–158. [PubMed]
122. Kurnik PB, Padmanabh U, Bonatsos C, Cynamon MH, Cynamon MH. 1983. Mycobacterium gordonae as a human hepato-peritoneal pathogen, with a review of the literature. Am J Med Sci 285:45–48. [PubMed]
123. Minamoto G, Armstrong D. 1986. Combating infections in patients with AIDS: update on the evolving epidemiology, issues in screening, and therapy. J Crit Illn 1:37–48.
124. Lim EJ, Johnson PD, Crowley P, Gow PJ. 2008. Granulomatous hepatitis: tuberculosis or not? Med J Aust 188:166–167. [PubMed]
125. Geri G, Cacoub P. 2011. Hepatic granulomas. Rev Med Interne 32:560–566. (In French.) [PubMed]
126. Bodurtha A, Kim YH, Laucius JF, Donato RA, Mastrangelo MJ. 1974. Hepatic granulomas and other hepatic lesions associated with BCG immunotherapy for cancer. Am J Clin Pathol 61:747–752. [PubMed]
127. Flippin T, Mukherji B, Dayal Y. 1980. Granulomatous hepatitis as a late complication of BCG immunotherapy. Cancer 46:1759–1762. [PubMed]
128. Gaya DR, Thorburn D, Oien KA, Morris AJ, Stanley AJ. 2003. Hepatic granulomas: a 10 year single centre experience. J Clin Pathol 56:850–853. [PubMed]
129. Göttke MU, Wong P, Muhn C, Jabbari M, Morin S. 2000. Hepatitis in disseminated bacillus Calmette-Guérin infection. Can J Gastroenterol 14:333–336. [PubMed]
130. Hunt JS, Silverstein MJ, Sparks FC, Haskell CM, Pilch YH, Morton DL. 1973. Granulomatous hepatitis: a complication of B.C.G. immunotherapy. Lancet ii:820–821.
131. Ozbakkaloglu B, Tünger O, Sürücüoglu S, Lekili M, Kandiloglu AR. 1999. Granulomatous hepatitis following intravesical bacillus Calmette-Guerin therapy. Int Urol Nephrol 31:49–53. [PubMed]
132. Shoaran M, Najafi M, Jalilian R, Rezaei N. 2013. Granulomatous hepatitis as a rare complication of Bacillus Calmette-Guérin vaccination. Ann Saudi Med 33:627–629. [PubMed]
133. O’Brien TF, Hyslop NE, Jr. 1975. Case records of the Massachusetts General Hospital, case 34-1975. N Engl J Med 293:443–448. [PubMed]
134. McKhann CF, Hendrickson CG, Spitler LE, Gunnarsson A, Banerjee D, Nelson WR. 1975. Immunotherapy of melanoma with BCG: two fatalities following intralesional injection. Cancer 35:514–520. [PubMed]
135. Krown SE, Hilal EY, Pinsky CM, Hirshaut Y, Wanebo HJ, Hansen JA, Huvos AG, Oettgen HF. 1978. Intralesional injection of the methanol extraction residue of Bacillus Calmette-Guerin (MER) into cutaneous metastases of malignant melanoma. Cancer 42:2648–2660.
136. Sparks FC, Albert NE, Breeding JH. 1977. Effect of isonicotinic acid hydrazide on the intratumor injection of BCG. J Natl Cancer Inst 58:367–368. [PubMed]
137. Govindasamy M, Srinivasan T, Varma V, Mehta N, Yadav A, Kumaran V, Nundy S. 2011. Biliary tract tuberculosis—a diagnostic dilemma. J Gastrointest Surg 15:2172–2177. [PubMed]
138. Stemmerman M. 1941. Bile duct tuberculosis. Q Bull Sea View Hosp 6:316–324.
139. Cruice JM. 1914. Jaundice in tuberculosis. Am J Med Sci 147:720–726.
140. Frank BB, Raffensperger EC. 1965. Hepatic granulomata: report of a case with jaundice improving on antituberculosis therapy and review of the literature. Arch Intern Med 115:223–234. [PubMed]
141. Abascal J, Martin F, Abreu L, Pereira F, Herrera J, Ratia T, Menendez J. 1988. Atypical hepatic tuberculosis presenting as obstructive jaundice. Am J Gastroenterol 83:1183–1186. [PubMed]
142. Murphy R, Swartz R, Watkins PB. 1990. Severe acetaminophen toxicity in a patient receiving isoniazid. Ann Intern Med 113:799–800. [PubMed]
143. Murphy TF, Gray GF. 1980. Biliary tract obstruction due to tuberculous adenitis. Am J Med 68:452–454. [PubMed]
144. Parthasarathy R, Sarma GR, Janardhanam B, Ramachandran P, Santha T, Sivasubramanian S, Somasundaram PR, Tripathy SP. 1986. Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 67:99–108. [PubMed]
145. Stanley JH, Yantis PL, Marsh WH. 1984. Periportal tuberculous adenitis: a rare cause of obstructive jaundice. Gastrointest Radiol 9:227–229. [PubMed]
146. Yeh TS, Chen NH, Jan YY, Hwang TL, Jeng LB, Chen MF. 1999. Obstructive jaundice caused by biliary tuberculosis: spectrum of the diagnosis and management. Gastrointest Endosc 50:105–108.
147. Bearer EA, Savides TJ, McCutchan JA. 1996. Endoscopic diagnosis and management of hepatobiliary tuberculosis. Am J Gastroenterol 91:2602–2604. [PubMed]
148. Colovic R, Grubor N, Jesic R, Micev M, Jovanovic T, Colovic N, Atkinson HD. 2008. Tuberculous lymphadenitis as a cause of obstructive jaundice: a case report and literature review. World J Gastroenterol 14:3098–3100. [PubMed]
149. Hickey N, McNulty JG, Osborne H, Finucane J. 1999. Acute hepatobiliary tuberculosis: a report of two cases and a review of the literature. Eur Radiol 9:886–889. [PubMed]
150. Arora R, Sharma A, Bhowate P, Bansal VK, Guleria S, Dinda AK. 2008. Hepatic tuberculosis mimicking Klatskin tumor: a diagnostic dilemma. Indian J Pathol Microbiol 51:382–385. [PubMed]
151. Sherlock S. 1985. The liver in infections, p 460–461. In Sherlock S (ed), Diseases of the Liver and Biliary System, 7th ed. Blackwell Science, Oxford, United Kingdom.
152. Kapoor S, Sewkani A, Naik S, Sharma S, Jain A, Varshney S. 2006. Myriad presentations of gall bladder tuberculosis. Indian J Gastroenterol 25:103–104. [PubMed]
153. Saluja SS, Ray S, Pal S, Kukeraja M, Srivastava DN, Sahni P, Chattopadhyay TK. 2007. Hepatobiliary and pancreatic tuberculosis: a two decade experience. BMC Surg 7:10. [PubMed]
154. Garber HI, Mason GR, Bouchelle WH. 1981. “Primary” miliary tuberculosis of the liver presenting as acute cholecystitis. Md State Med J 30:73–74. [PubMed]
155. Siemann M, Rabenhorst G, Bramann A, Renk C. 1999. A case of cryptic miliary tuberculosis mimicking cholecystitis with sepsis. Infection 27:44–45. [PubMed]
156. Rozmanić V, Kilvain S, Ahel V, Banac S, Gazdik M. 2001. Pulmonary tuberculosis with gallbladder involvement: a review and case report. Pediatr Int 43:511–513. [PubMed]
157. Ben RJ, Young T, Lee HS. 1995. Hepatobiliary tuberculosis presenting as a gall bladder tumor. Scand J Infect Dis 27:415–417. [PubMed]
158. Auerbach O. 1944. Acute generalized miliary tuberculosis. Am J Pathol 20:121–136. [PubMed]
159. Ladas SD, Vaidakis E, Lariou C, Anastasiou K, Chalevelakis G, Kintzonidis D, Raptis SA. 1998. Pancreatic tuberculosis in non-immunocompromised patients: reports of two cases, and a literature review. Eur J Gastroenterol Hepatol 10:973–976. [PubMed]
160. Xia F, Poon RT, Wang SG, Bie P, Huang XQ, Dong JH. 2003. Tuberculosis of pancreas and peripancreatic lymph nodes in immunocompetent patients: experience from China. World J Gastroenterol 9:1361–1364. [PubMed]
161. Nagar AM, Raut AA, Morani AC, Sanghvi DA, Desai CS, Thapar VB. 2009. Pancreatic tuberculosis: a clinical and imaging review of 32 cases. J Comput Assist Tomogr 33:136–141. [PubMed]
162. Song TJ, Lee SS, Park DH, Lee TY, Lee SO, Seo DW, Lee SK, Kim M-H. 2009. Yield of EUS-guided FNA on the diagnosis of pancreatic/peripancreatic tuberculosis. Gastrointest Endosc 69(Suppl 1):484–491. [PubMed]
163. Cho SB. 2009. Pancreatic tuberculosis presenting with pancreatic cystic tumor: a case report and review of the literature. Korean J Gastroenterol 53:324–328. [PubMed]
164. Ibrahim GF, Al-Nakshabandi NA. 2011. Pancreatic tuberculosis: role of multidetector computed tomography. Can Assoc Radiol J 62:260–264. [PubMed]
165. Meesiri S. 2012. Pancreatic tuberculosis with AIDS: a case report and systematic review. World J Gastroenterol 18:720–726. [PubMed]
166. Puri R, Thandassery RB, Eloubeidi MA, Sud R. 2012. Diagnosis of isolated pancreatic tuberculosis: the role of EUS-guided FNA cytology. Gastrointest Endosc 75:900–904. [PubMed]
167. Kim JB, Lee SS, Kim SH, Byun JH, Park DH, Lee TY, Lee BU, Jeong SU, Seo DW, Lee SK, Kim M-H. 2014. Peripancreatic tuberculous lymphadenopathy masquerading as pancreatic malignancy: a single-center experience. J Gastroenterol Hepatol 29:409–416. [PubMed]
168. Woodfield JC, Windsor JA, Godfrey CC, Orr DA, Officer NM. 2004. Diagnosis and management of isolated pancreatic tuberculosis: recent experience and literature review. ANZ J Surg 74:368–371. [PubMed]
169. Demir K, Kaymakoglu S, Besisik F, Durakoglu Z, Ozdil S, Kaplan Y, Boztas G, Cakaloglu Y, Okten A. 2001. Solitary pancreatic tuberculosis in immunocompetent patients mimicking pancreatic carcinoma. J Gastroenterol Hepatol 16:1071–1074. [PubMed]
170. Franco-Paredes C, Leonard M, Jurado R, Blumberg HM, Smith RM. 2002. Tuberculosis of the pancreas: report of two cases and review of the literature. Am J Med Sci 323:54–58. [PubMed]
171. Rezeig MA, Fashir BM, Al-Suhaibani H, Al-Fadda M, Amin T, Eisa H. 1998. Pancreatic tuberculosis mimicking pancreatic carcinoma: four case reports and review of the literature. Dig Dis Sci 43:329–331. [PubMed]
172. Turan M, Sen M, Koyuncu A, Aydin C, Elaldi N, Arici S. 2002. Pancreatic pseudotumor due to peripancreatic tuberculous lymphadenitis. Pancreatology 2:561–564. [PubMed]
173. Schneider A, von Birgelen C, Dührsen U, Gerken G, Rünzi M. 2002. Two cases of pancreatic tuberculosis in nonimmunocompromised patients. A diagnostic challenge and a rare cause of portal hypertension. Pancreatology 2:69–73.
174. Laamrani FZ, Dafiri R. 2014. A rare pediatric case of pancreatic tuberculosis with veinous thrombosis. Diagn Interv Imaging 95:455–456. [PubMed]
175. Irfan M, Thiavalappil F, Nagaraj J, Brown TH, Roberts D, McKnight L, Harrison NK. 2013. Tuberculous pancreatitis complicated by ruptured splenic artery pseudoaneurysm. Monaldi Arch Chest Dis 79:134–135. [PubMed]
176. Pombo F, Díaz Candamio MJ, Rodriguez E, Pombo S. 1998. Pancreatic tuberculosis: CT findings. Abdom Imaging 23:394–397. [PubMed]
177. Jenney AW, Pickles RW, Hellard ME, Spelman DW, Fuller AJ, Spicer WJ. 1998. Tuberculous pancreatic abscess in an HIV antibody-negative patient: case report and review. Scand J Infect Dis 30:99–104. [PubMed]
178. Fee MJ, Oo MM, Gabayan AE, Radin DR, Barnes PF. 1995. Abdominal tuberculosis in patients infected with the human immunodeficiency virus. Clin Infect Dis 20:938–944. [PubMed]
179. Maniar JK, Kamath RR, Mandalia S, Shah K, Maniar A. 2006. HIV and tuberculosis: partners in crime. Indian J Dermatol Venereol Leprol 72:276–282. [PubMed]
180. Jaber B, Gleckman R. 1995. Tuberculous pancreatic abscess as an initial AIDS-defining disorder in a patient infected with the human immunodeficiency virus: case report and review. Clin Infect Dis 20:890–894. [PubMed]
181. Agrawal HS, Benson JW, Major JJ. 1967. An unusual case of hemobilia. Hepatic tuberculosis with hemorrhage. Arch Surg 95:202–206. [PubMed]
182. Elte PM, van Aken WG, Agenant DM, Tijtgat GN. 1980. Hemobilia after liver biopsy. Early detection in a patient with mild hemophilia A. Arch Intern Med 140:839–840. [PubMed]
183. Levinson JD, Olsen G, Terman JW, Cleaveland CR, Graham CP, Jr, Breen KJ. 1972. Hemobilia secondary to percutaneous liver biopsy. Arch Intern Med 130:396–400. [PubMed]
184. Lewis J, Varma V, Tice H, Steinberg W, Reba R. 1982. Hepatobiliary scanning in hemobilia-induced acute cholecystitis. Gastrointest Radiol 7:169–171. [PubMed]
185. Das D, Mandal SK, Majumder D, De BK. 2003. Disseminated tuberculosis presenting as hemobilia, successfully treated by arterial embolization. J Assoc Physicians India 51:229–231. [PubMed]
186. Beeresha LH, Ghotekar LH, Dutta TK, Verma SK, Elangovan S. 2000. Hepatic artery mycotic aneurysm of tubercular aetiology. J Assoc Physicians India 48:247–248. [PubMed]
187. Dock W, Grabenwöger F, Bardach G, Pinterits F, Klepetko W, Laufer G. 1987. An unusual cause of haemobilia. Br J Radiol 60:1228–1229. [PubMed]
188. Devars du Mayne JF, Marche C, Penalba C, Vittecoq D, Saimot G, Cerf M. 1985. Liver disease in acquired immune deficiency syndrome: study of 20 cases. Presse Med 14:1177–1180. [PubMed]
189. Glasgow BJ, Anders K, Layfield LJ, Steinsapir KD, Gitnick GL, Lewin KJ. 1985. Clinical and pathologic findings of the liver in the acquired immune deficiency syndrome (AIDS). Am J Clin Pathol 83:582–588. [PubMed]
190. Guarda LA, Luna MA, Smith JL, Jr, Mansell PW, Gyorkey F, Roca AN. 1984. Acquired immune deficiency syndrome: postmortem findings. Am J Clin Pathol 81:549–557. [PubMed]
191. Lebovics E, Thung SN, Schaffner F, Radensky PW. 1985. The liver in the acquired immunodeficiency syndrome: a clinical and histologic study. Hepatology 5:293–298. [PubMed]
192. Lewis JH, Winston BJ, Garone MA, Farhood A. 1985. The liver in AIDS: a clinicopathologic correlation. Gastroenterology 88:1675.
193. Orenstein MS, Tavitian A, Yonk B, Dincsoy HP, Zerega J, Iyer SK, Straus EW. 1985. Granulomatous involvement of the liver in patients with AIDS. Gut 26:1220–1225. [PubMed]
194. Reichert CM, O’Leary TJ, Levens DL, Simrell CR, Macher AM. 1983. Autopsy pathology in the acquired immune deficiency syndrome. Am J Pathol 112:357–382. [PubMed]
195. Schneiderman DJ, Arenson DM, Cello JP. 1986. Hepatic disease in patients with the acquired immune deficiency syndrome. Gastroenterology 90:1620.
196. Armstrong D, Gold JWN, Dryjanski J, Whimbey E, Polsky B, Hawkins C, Brown AE, Bernard E, Kiehn TE. 1985. Treatment of infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med 103:738–743. [PubMed]
197. Sanabe N, Ikematsu Y, Nishiwaki Y, Kida H, Murohisa G, Ozawa T, Hasegawa S, Okawada T, Toritsuka T, Waki S. 2002. Pancreatic tuberculosis. J Hepatobiliary Pancreat Surg 9:515–518. [PubMed]
198. Selwyn PA, Lewis VA, Schoenbaum EE. 1988. HIV infection and tuberculosis in intravenous drug users in a methadone program, abstr 7549. Proc IVth Int Conf AIDS, Stockholm, Sweden.
199. Sunderam G, McDonald RJ, Maniatis T, Oleske J, Kapila R, Reichman LB. 1986. Tuberculosis as a manifestation of the acquired immunodeficiency syndrome (AIDS). JAMA 256:362–366. [PubMed]
200. Markowitz N, Hansen NI, Hopewell PC, Glassroth J, Kvale PA, Mangura BT, Wilcosky TC, Wallace JM, Rosen MJ, Reichman LB, The Pulmonary Complications of HIV Infection Study Group. 1997. Incidence of tuberculosis in the United States among HIV-infected persons. Ann Intern Med 126:123–132. [PubMed]
201. Kumar R, Kapoor D, Singh J, Kumar N. 2003. Isolated tuberculosis of the pancreas: a report of two cases and review of the literature. Trop Gastroenterol 24:76–78. [PubMed]
202. Poprawski D, Pitisuttitum P, Tansuphasawadikul S. 2000. Clinical presentations and outcomes of TB among HIV-positive patients. Southeast Asian J Trop Med Public Health 31(Suppl 1):140–142. [PubMed]
203. Smith MB, Boyars MC, Veasey S, Woods GL. 2000. Generalized tuberculosis in the acquired immune deficiency syndrome. Arch Pathol Lab Med 124:1267–1274. [PubMed]
204. Abdel-Dayem HM, Naddaf S, Aziz M, Mina B, Turoglu T, Akisik MF, Omar WS, DiFabrizio L, LaBombardi V, Kempf JS. 1997. Sites of tuberculous involvement in patients with AIDS. Autopsy findings and evaluation of gallium imaging. Clin Nucl Med 22:310–314. [PubMed]
205. Gonzalez OY, Adams G, Teeter LD, Bui TT, Musser JM, Graviss EA. 2003. Extra-pulmonary manifestations in a large metropolitan area with a low incidence of tuberculosis. Int J Tuberc Lung Dis 7:1178–1185. [PubMed]
206. Meintjes G, Sonderup M. 2011. A practical approach to the diagnosis and management of paradoxical tuberculosis immune reconstitution inflammatory syndrome. Contin Med Educ 29:410–415.
207. Liberato IR, de Albuquerque MF, Campelo AR, de Melo HR. 2004. Characteristics of pulmonary tuberculosis in HIV seropositive and seronegative patients in a Northeastern region of Brazil. Rev Soc Bras Med Trop 37:46–50. [PubMed]
208. Sattler FR, Cowan R, Nielsen DM, Ruskin J. 1988. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. Ann Intern Med 109:280–287. [PubMed]
209. Ozick LA, Jacob L, Comer GM, Lee TP, Ben-Zvi J, Donelson SS, Felton CP. 1995. Hepatotoxicity from isoniazid and rifampin in inner-city AIDS patients. Am J Gastroenterol 90:1978–1980. [PubMed]
210. Amarapurkar DN, Chopra KB, Phadke AY, Sahni S, Prabhu SR, Kalro RH. 1995. Tuberculous abscess of the liver associated with HIV infection. Indian J Gastroenterol 14:21–22. [PubMed]
211. Probst A, Schmidbaur W, Jechart G, Hammond A, Zentner J, Niculescu E, Messmann H. 2004. Obstructive jaundice in AIDS: diagnosis of biliary tuberculosis by ERCP. Gastrointest Endosc 60:145–148. [PubMed]
212. Horsburgh CR, Jr, Metchock B, Gordon SM, Havlik JA, Jr, McGowan JE, Jr, Thompson SE, III. 1994. Predictors of survival in patients with AIDS and disseminated Mycobacterium avium complex disease. J Infect Dis 170:573–577. [PubMed]
213. Chaisson RE, Moore RD, Richman DD, Keruly J, Creagh T, The Zidovudine Epidemiology Study Group. 1992. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. Am Rev Respir Dis 146:285–289. [PubMed]
214. Tarantino L, Giorgio A, de Stefano G, Farella N, Perrotta A, Esposito F. 2003. Disseminated mycobacterial infection in AIDS patients: abdominal US features and value of fine-needle aspiration biopsy of lymph nodes and spleen. Abdom Imaging 28:602–608. [PubMed]
215. Hawkins CC, Gold JWM, Whimbey E, Kiehn TE, Brannon P, Cammarata R, Brown AE, Armstrong D. 1986. Mycobacterium avium complex infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med 105:184–188. [PubMed]
216. Kiehn TE, Edwards FF, Brannon P, Tsang AY, Maio M, Gold JW, Whimbey E, Wong B, McClatchy JK, Armstrong D. 1985. Infections caused by Mycobacterium avium complex in immunocompromised patients: diagnosis by blood culture and fecal examination, antimicrobial susceptibility tests, and morphological and seroagglutination characteristics. J Clin Microbiol 21:168–173. [PubMed]
217. O’Brien RJ, Lyle MA, Johnson MW, Snider DE. 1985. Ansamycin LM427 therapy in AIDS patients with Mycobacterium avium (MAI) complex infection: a preliminary report, p 47. Abstr Int Conf Acquir Immunodefic Syndr. American College of Physicians, Philadelphia, PA.
218. Wong B, Edwards FF, Kiehn TE, Whimbey E, Donnelly H, Bernard EM, Gold JW, Armstrong D. 1985. Continuous high-grade Mycobacterium avium-intracellulare bacteremia in patients with the acquired immune deficiency syndrome. Am J Med 78:35–40. [PubMed]
219. Shafran SD, Singer J, Zarowny DP, Phillips P, Salit I, Walmsley SL, Fong IW, Gill MJ, Rachlis AR, Lalonde RG, Fanning MM, Tsoukas CM. 1996. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. N Engl J Med 335:377–383. [PubMed]
220. Singh N, Paterson DL. 1998. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis 27:1266–1277. [PubMed]
221. Muñoz P, Rodríguez C, Bouza E. 2005. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis 40:581–587. [PubMed]
222. Torre-Cisneros J, Doblas A, Aguado JM, San Juan R, Blanes M, Montejo M, Cervera C, Len O, Carratala J, Cisneros JM, Bou G, Muñoz P, Ramos A, Gurgui M, Borrell N, Fortún J, Moreno A, Gavalda J, Spanish Network for Research in Infectious Diseases. 2009. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis 48:1657–1665. [PubMed]
223. Aguado JM, Herrero JA, Gavaldá J, Torre-Cisneros J, Blanes M, Rufí G, Moreno A, Gurguí M, Hayek M, Lumbreras C, Cantarell C. 1997. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Transplantation 63:1278–1286. [PubMed]
224. Singh N, Wagener MM, Gayowski T. 2002. Safety and efficacy of isoniazid chemoprophylaxis administered during liver transplant candidacy for the prevention of posttransplant tuberculosis. Transplantation 74:892–895. [PubMed]
225. Holty JE, Gould MK, Meinke L, Keeffe EB, Ruoss SJ. 2009. Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data. Liver Transpl 15:894–906. [PubMed]
226. Bodro M, Sabé N, Santín M, Cruzado JM, Lladó L, González-Costello J, Carratalà J. 2012. Clinical features and outcomes of tuberculosis in solid organ transplant recipients. Transplant Proc 44:2686–2689. [PubMed]
227. Meyers BR, Halpern M, Sheiner P, Mendelson MH, Neibart E, Miller C. 1994. Tuberculosis in liver transplant patients. Transplantation 58:301–306. [PubMed]
228. Grauhan O, Lohmann R, Lemmens P, Schattenfroh N, Jonas S, Keck H, Raakow R, Langrehr J, Bechstein W, Blumhardt G, Klein E, Neuhaus P. 1995. Mycobacterial infection after liver transplantation. Langenbecks Arch Chir 380:171–175. [PubMed]
229. Ferrell LD, Lee R, Brixko C, Bass NM, Lake JR, Roberts JP, Ascher N, Rabkin J. 1995. Hepatic granulomas following liver transplantation. Clinicopathologic features in 42 patients. Transplantation 60:926–933. [PubMed]
230. Hsu MS, Wang JL, Ko WJ, Lee PH, Chou NK, Wang SS, Chu SH, Chang SC. 2007. Clinical features and outcome of tuberculosis in solid organ transplant recipients. Am J Med Sci 334:106–110. [PubMed]
231. Schluger LK, Sheiner PA, Jonas M, Guarrera JV, Fiel IM, Meyers B, Berk PD. 1996. Isoniazid hepatotoxicity after orthotopic liver transplantation. Mt Sinai J Med 63:364–369. [PubMed]
232. Torre-Cisneros J, Castón JJ, Moreno J, Rivero A, Vidal E, Jurado R, Kindelán JM. 2004. Tuberculosis in the transplant candidate: importance of early diagnosis and treatment. Transplantation 77:1376–1380. [PubMed]
233. Benito N, Sued O, Moreno A, Horcajada JP, González J, Navasa M, Rimola A. 2002. Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area. Transplantation 74:1381–1386. [PubMed]
234. Torre-Cisneros J, de la Mata M, Rufian S, Villanueva Marcos JL, Gutierrez Aroca J, Casal M, Miño G, Pera C. 1995. Importance of surveillance mycobacterial cultures after liver transplantation. Transplantation 60:1054–1055. [PubMed]
235. Subramanian AK, Morris MI, AST Infectious Diseases Community of Practice. 2013. Mycobacterium tuberculosis infections in solid organ transplantation. Am J Transplant 13(Suppl 4):68–76. [PubMed]
236. Meyers BR, Papanicolaou GA, Sheiner P, Emre S, Miller C. 2000. Tuberculosis in orthotopic liver transplant patients: increased toxicity of recommended agents; cure of disseminated infection with nonconventional regimens. Transplantation 69:64–69. [PubMed]
237. Thora S, Chansoria M, Kaul KK. 1985. Congenital tuberculosis: a case with unusual features. Indian J Pediatr 52:425–427. [PubMed]
238. Verma A, Dhawan A, Wade JJ, Lim WH, Ruiz G, Price JF, Hadzic N, Baker AJ, Rela M, Heaton ND, Mieli-Vergani G. 2000. Mycobacterium tuberculosis infection in pediatric liver transplant recipients. Pediatr Infect Dis J 19:625–630. [PubMed]
239. Sun HY, Munoz P, Torre-Cisneros J, Aguado JM, Lattes R, Montejo M, Garcia-Reyne A, Bouza E, Valerio M, Lara R, John GT, Bruno D, Singh N. 2013. Mycobacterium tuberculosis-associated immune reconstitution syndrome in solid-organ transplant recipients. Transplantation 95:1173–1181. [PubMed]
240. Rolleston H, McNee JW. 1929. Diseases of the Liver, Gallbladder and Bile Ducts. Macmillan, London, United Kingdom.
241. Karsner HT. 1943. Morphology and pathogenesis of hepatic cirrhosis. Am J Clin Pathol 13:569–606.
242. Gelb AM, Brazenas N, Sussman H, Wallach R. 1970. Acute granulomatous disease of the liver. Am J Dig Dis 15:842–847. [PubMed]
243. Fitzgerald GR, Grimes H, Reynolds M, Hitchcock H, McCarthy CF. 1975. Hepatitis-associated-antigen-positive hepatitis in a tuberculosis unit. Gut 16:421–428. [PubMed]
244. McGlynn KA, Lustbader ED, London WT. 1985. Immune responses to hepatitis B virus and tuberculosis infections in Southeast Asian refugees. Am J Epidemiol 122:1032–1036. [PubMed]
245. Wu J-C, Lee S-D, Yeh P-F, Chan CY, Wang YJ, Huang YS, Tsai YT, Lee PY, Ting LP, Lo KJ. 1990. Isoniazid-rifampin-induced hepatitis in hepatitis B carriers. Gastroenterology 98:502–504. [PubMed]
246. Pan L, Jia ZS, Chen L, Fu EQ, Li GY. 2005. Effect of anti-tuberculosis therapy on liver function of pulmonary tuberculosis patients infected with hepatitis B virus. World J Gastroenterol 11:2518–2521. [PubMed]
247. Trigo C, do Brasil PE, Costa MJ, de Castro L. 13 September 2016. Occult hepatitis B virus infection: clinical implications in tuberculosis treatment. J Viral Hepat doi:10.1111/jvh.12583.
248. Cho YJ, Lee SM, Yoo CG, Kim YW, Han SK, Shim YS, Yim JJ. 2007. Clinical characteristics of tuberculosis in patients with liver cirrhosis. Respirology 12:401–405. [PubMed]
249. Shin HJ, Lee HS, Kim YI, Lim SC, Jung JP, Ko YC, Kwon YS. 2014. Hepatotoxicity of anti-tuberculosis chemotherapy in patients with liver cirrhosis. Int J Tuberc Lung Dis 18:347–351. [PubMed]
250. Nishioka SA. 1996. Cirrhosis as a risk factor to drug-resistant tuberculosis. Eur Respir J 9:2188–2189. [PubMed]
251. Bagnato GF, Di Cesare E, Gulli S, Cucinotta D. 1995. Long-term treatment of pulmonary tuberculosis with ofloxacin in a subject with liver cirrhosis. Monaldi Arch Chest Dis 50:279–281. [PubMed]
252. Rougier P, Degott C, Rueff B, Benhamou JP. 1978. Nodular regenerative hyperplasia of the liver. Report of six cases and review of the literature. Gastroenterology 75:169–172. [PubMed]
253. Steiner PE. 1959. Nodular regenerative hyperplasia of the liver. Am J Pathol 35:943–953. [PubMed]
254. Wanless IR, Solt LC, Kortan P, Deck JH, Gardiner GW, Prokipchuk EJ. 1981. Nodular regenerative hyperplasia of the liver associated with macroglobulinemia. A clue to the pathogenesis. Am J Med 70:1203–1209.
255. Boursier J, Foulet A, Pilette C. 2005. Nodular regenerative hyperplasia following liver tuberculosis. Gastroenterol Clin Biol 29:1051–1053. (In French.)
256. Gordeuk VR, McLaren CE, MacPhail AP, Deichsel G, Bothwell TH. 1996. Associations of iron overload in Africa with hepatocellular carcinoma and tuberculosis: Strachan’s 1929 thesis revisited. Blood 87:3470–3476. [PubMed]
257. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. 2008. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 23:192–202. [PubMed]
258. Marzuki OA, Fauzi AR, Ayoub S, Kamarul Imran M. 2008. Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia. Singapore Med J 49:688–693. [PubMed]
259. Sun Q, Zhang Q, Gu J, Sun WW, Wang P, Bai C, Xiao HP, Sha W. 2016. Prevalence, risk factors, management, and treatment outcomes of first-line antituberculous drug-induced liver injury: a prospective cohort study. Pharmacoepidemiol Drug Saf 25:908–917. [PubMed]
260. Abera W, Cheneke W, Abebe G. 2016. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: a cohort study. Int J Mycobacteriol 5:14–20. [PubMed]
261. Sarda P, Sharma SK, Mohan A, Makharia G, Jayaswal A, Pandey RM, Singh S. 2009. Role of acute viral hepatitis as a confounding factor in ATT induced hepatotoxicity. Indian J Med Res 129:64–67. [PubMed]
262. Sharma SK, Singla R, Sarda P, Mohan A, Makharia G, Jayaswal A, Sreenivas V, Singh S. 2010. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis 50:833–839. [PubMed]
263. Zimmerman HJ, Lewis JH. 1984. Hepatic toxicity of antimicrobial agents, p 153–201. In Root RK, Sande MA (ed), New Dimensions in Antimicrobial Therapy. Churchill Livingstone, New York, NY.
264. Zimmerman HJ. 1978. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver, p 485–495. Appleton-Century-Crofts, New York, NY.
265. Mitchell JR, Zimmerman HJ, Ishak KG, Thorgeirsson UP, Timbrell JA, Snodgrass WR, Nelson SD. 1976. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med 84:181–192. [PubMed]
266. Snider DE, Jr, Caras GJ. 1992. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis 145:494–497. [PubMed]
267. Franks AL, Binkin NJ, Snider DE, Jr, Rokaw WM, Becker S. 1989. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep 104:151–155. [PubMed]
268. Fernández-Villar A, Sopeña B, Vázquez R, Ulloa F, Fluiters E, Mosteiro M, Martínez-Vázquez C, Piñeiro L. 2003. Isoniazid hepatotoxicity among drug users: the role of hepatitis C. Clin Infect Dis 36:293–298. [PubMed]
269. Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, Pitchenik AE. 1998. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 157:1871–1876. [PubMed]
270. Wong WM, Wu PC, Yuen MF, Cheng CC, Yew WW, Wong PC, Tam CM, Leung CC, Lai CL. 2000. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 31:201–206. [PubMed]
271. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. 2003. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 167:1472–1477. [PubMed]
272. Mindikoglu AL, Magder LS, Regev A. 2009. Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database. Liver Transpl 15:719–729. [PubMed]
273. Centers for Disease Control and Prevention. 2010. Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection—United States, 2004–2008. MMWR Morb Mortal Wkly Rep 59:224–229. [PubMed]
274. Barcena R, Oton E, Angeles Moreno M, Fortún J, Garcia-Gonzalez M, Moreno A, de Vicente E. 2005. Is liver transplantation advisable for isoniazid fulminant hepatitis in active extrapulmonary tuberculosis? Am J Transplant 5:2796–2798. [PubMed]
275. Lewis JH, Zimmerman HJ. 1989. Drug-induced liver disease. Med Clin North Am 73:775–792. [PubMed]
276. Metushi I, Uetrecht J, Phillips E. 2016. Mechanism of isoniazid-induced hepatotoxicity: then and now. Br J Clin Pharmacol 81:1030–1036. [PubMed]
277. McDonagh EM, Boukouvala S, Aklillu E, Hein DW, Altman RB, Klein TE. 2014. PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2. Pharmacogenet Genomics 24:409–425.
278. Mitchell JR, Thorgeirsson UP, Black M, Timbrell JA, Snodgrass WR, Potter WZ, Jollow HR, Keiser HR. 1975. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther 18:70–79. [PubMed]
279. Ng CS, Hasnat A, Al Maruf A, Ahmed MU, Pirmohamed M, Day CP, Aithal GP, Daly AK. 2014. N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group. Eur J Clin Pharmacol 70:1079–1086. [PubMed]
280. Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, Chang FY, Lee SD. 2002. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35:883–889. [PubMed]
281. Wang PY, Xie SY, Hao Q, Zhang C, Jiang BF. 2012. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis 16:589–595. [PubMed]
282. Guaoua S, Ratbi I, El Bouazzi O, Hammi S, Tebaa A, Bourkadi JE, Bencheikh RS, Sefiani A. 2016. NAT2 genotypes in Moroccan patients with hepatotoxicity due to antituberculosis drugs. Genet Test Mol Biomarkers 20:680–684. [PubMed]
283. Ben Fredj N, Gam R, Kerkni E, Chaabane A, Chadly Z, Boughattas N, Aouam K. 19 April 2016. Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients. Pharmacogenomics J doi:10.1038/tpj.2016.26.
284. Nolan CM, Sandblom RE, Thummel KE, Slattery JT, Nelson SD. 1994. Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. Chest 105:408–411. [PubMed]
285. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR, ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee. 2006. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 174:935–952. [PubMed]
286. Vanhoof J, Landewe S, Van Wijngaerden E, Geusens P. 2003. High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors. Ann Rheum Dis 62:1241–1242. [PubMed]
287. Berkowitz FE, Henderson SL, Fajman N, Schoen B, Naughton M. 1998. Acute liver failure caused by isoniazid in a child receiving carbamazepine. Int J Tuberc Lung Dis 2:603–606. [PubMed]
288. Moulding TS, Redeker AG, Kanel GC. 1989. Twenty isoniazid-associated deaths in one state. Am Rev Respir Dis 140:700–705. [PubMed]
289. Fresard I, Bridevaux PO, Rochat T, Janssens JP. 2011. Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis. Swiss Med Wkly 141:w13240. [PubMed]
290. Fountain FF, Tolley EA, Jacobs AR, Self TH. 2009. Rifampin hepatotoxicity associated with treatment of latent tuberculosis infection. Am J Med Sci 337:317–320. [PubMed]
291. Askgaard DS, Wilcke T, Døssing M. 1995. Hepatotoxicity caused by the combined action of isoniazid and rifampicin. Thorax 50:213–214. [PubMed]
292. Steele MA, Burk RF, DesPrez RM. 1991. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 99:465–471. [PubMed]
293. Scheuer PJ, Summerfield JA, Lal S, Sherlock S. 1974. Rifampicin hepatitis. A clinical and histological study. Lancet i:421–425. [PubMed]
294. Durand F, Bernuau J, Pessayre D, Samuel D, Belaiche J, Degott C, Bismuth H, Belghiti J, Erlinger S, Rueff B, Benhamou JP. 1995. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. Hepatology 21:929–932. [PubMed]
295. Mitchell I, Wendon J, Fitt S, Williams R. 1995. Anti-tuberculous therapy and acute liver failure. Lancet 345:555–556. [PubMed]
296. Centers for Disease Control and Prevention, American Thoracic Society. 2003. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection—United States, 2003. MMWR Morb Mortal Wkly Rep 52:735–739. [PubMed]
297. Ijaz K, Jereb JA, Lambert LA, Bower WA, Spradling PR, McElroy PD, Iademarco MF, Navin TR, Castro KG. 2006. Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis 42:346–355. [PubMed]
298. Horita N, Miyazawa N. 2015. Drug-induced liver injury and pyrazinamide use. Kekkaku 90:401–405. [PubMed]
299. Guo HL, Hassan HM, Zhang Y, Dong SZ, Ding PP, Wang T, Sun LX, Zhang LY, Jiang ZZ. 2016. Pyrazinamide induced rat cholestatic liver injury through inhibition of FXR regulatory effect on bile acid synthesis and transport. Toxicol Sci 152:417–428. [PubMed]
300. Pierce M, Crampton S, Henry D, Heifets L, LaMarca A, Montecalvo M, Wormser GP, Jablonowski H, Jemsek J, Cynamon M, Yangco BG, Notario G, Craft JC. 1996. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 335:384–391. [PubMed]
301. Yew WW, Chau CH, Lee J, Leung CW. 1995. Cholestatic hepatitis in a patient who received clarithromycin therapy for a Mycobacterium chelonae lung infection. Clin Infect Dis 20:1073–1074.
302. Ho CC, Chen YC, Hu FC, Yu CJ, Yang PC, Luh KT. 2009. Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens. Clin Infect Dis 48:1526–1533. [PubMed]
303. Leise MD, Poterucha JJ, Talwalkar JA. 2014. Drug-induced liver injury. Mayo Clin Proc 89:95–106. [PubMed]
304. Nolan CM, Goldberg SV, Buskin SE. 1999. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 281:1014–1018. [PubMed]
305. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O’Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA, American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. 2003. Treatment of tuberculosis. Am J Respir Crit Care Med 167:603–662. [PubMed]
306. Saukkonen JJ, Powell K, Jereb JA. 2012. Monitoring for tuberculosis drug hepatotoxicity: moving from opinion to evidence. Am J Respir Crit Care Med 185:598–599. [PubMed]
307. Singanayagam A, Sridhar S, Dhariwal J, Abdel-Aziz D, Munro K, Connell DW, George PM, Molyneaux PL, Cooke GS, Burroughs AK, Lalvani A, Wickremasinghe M, Kon OM. 2012. A comparison between two strategies for monitoring hepatic function during antituberculous therapy. Am J Respir Crit Care Med 185:653–659. [PubMed]
308. Hayashi PH, Fontana RJ, Chalasani NP, Stolz AA, Talwalkar JA, Navarro VJ, Lee WM, Davern TJ, Kleiner DE, Gu J, Hoofnagle JH, US Drug-Induced Liver Injury Network Investigators. 2015. Under reporting and poor adherence to monitoring guidelines for severe cases of isoniazid hepatotoxicity. Clin Gastroenterol Hepatol 13:1676–82.e1. [PubMed]
309. Lewis JH. 2002. The rational use of potentially hepatotoxic medications in patients with underlying liver disease. Expert Opin Drug Saf 1:159–172. [PubMed]
310. Centers for Disease Control and Prevention. 1993. Severe isoniazid-associated hepatitis—New York, 1991–1993. MMWR Morb Mortal Wkly Rep 42:545–547. [PubMed]
311. Noble A, Janes SL, Behrens J. 1995. Antituberculous therapy and acute liver failure. Lancet 345:867.
312. Hatamkhani S, Khalili H, Karimzadeh I, Dashti-Khavidaki S, Abdollahi A, Jafari S. 2014. Carnitine for prevention of antituberculosis drug-induced hepatotoxicity: a randomized, clinical trial. J Gastroenterol Hepatol 29:997–1004. [PubMed]
313. Martin SJ, Baskaran UL, Vedi M, Sabina EP. 2014. Attenuation of anti-tuberculosis therapy induced hepatotoxicity by Spirulina fusiformis, a candidate food supplement. Toxicol Mech Methods 24:584–592. [PubMed]
314. Jaswal A, Sinha N, Bhadauria M, Shrivastava S, Shukla S. 2013. Therapeutic potential of thymoquinone against anti-tuberculosis drugs induced liver damage. Environ Toxicol Pharmacol 36:779–786. [PubMed]
315. Enriquez-Cortina C, Almonte-Becerril M, Clavijo-Cornejo D, Palestino-Domínguez M, Bello-Monroy O, Nuño N, López A, Bucio L, Souza V, Hernández-Pando R, Muñoz L, Gutiérrez-Ruiz MC, Gómez-Quiroz LE. 2013. Hepatocyte growth factor protects against isoniazid/rifampicin-induced oxidative liver damage. Toxicol Sci 135:26–36. [PubMed]
316. Liu Q, Garner P, Wang Y, Huang B, Smith H. 2008. Drugs and herbs given to prevent hepatotoxicity of tuberculosis therapy: systematic review of ingredients and evaluation studies. BMC Public Health 8:365. [PubMed]
317. Zhang S, Pan H, Peng X, Lu H, Fan H, Zheng X, Xu G, Wang M, Wang J. 2016. Preventive use of a hepatoprotectant against anti-tuberculosis drug-induced liver injury: a randomized controlled trial. J Gastroenterol Hepatol 31:409–416. [PubMed]
318. Van Buchem FSP. 1946. On morbid conditions of liver and diagnosis of disease of Besnier-Boeck-Shauman. Acta Med Scand 124:168–184.
319. Von Oldershausen HF, Von Oldershausen R, Tellesz A. 1955. Zur Klinik und pathogenetischen Bedeutung der sogenannten granulomatösen Hepatopathie bei der Tuberkulose. Klin Wochenschr 33:104–114. [PubMed]
320. Arora MM, Ali A, D’Souza AJ, Pawar KN. 1956. Clinical, functional, and needle biopsy studies of the liver in tuberculosis. J Indian Med Assoc 26:341–344. [PubMed]
321. Salib M, Le Golvan PC, Arm HG, Sabour M, Shehata EE. 1961. Clinical histopathological and bacteriological study of the liver in chronic fibrocaseous pulmonary tuberculosis. J Egypt Med Assoc 44:226–234. [PubMed]
322. Gupta S, Meena HS, Chopra R. 1993. Hepatic involvement in tuberculosis. J Assoc Physicians India 41:20–22. [PubMed]
323. Amarapurkar A, Agrawal V. 2006. Liver involvement in tuberculosis—an autopsy study. Trop Gastroenterol 27:69–74. [PubMed]
324. Biehl JP. 1958. Miliary tuberculosis; a review of sixty-eight adult patients admitted to a municipal general hospital. Am Rev Tuberc 77:605–622. [PubMed]
325. Gelb AF, Leffler C, Brewin A, Mascatello V, Lyons HA. 1973. Miliary tuberculosis. Am Rev Respir Dis 108:1327–1333. [PubMed]
326. Sinha SK, Chatterjee M, Bhattacharya S, Pathak SK, Mitra RB, Karak K, Mukherjee M. 2003. Diagnostic evaluation of extrapulmonary tuberculosis by fine needle aspiraton (FNA) supplemented with AFB smear and culture. J Indian Med Assoc 101:588, 590–591. [PubMed]
327. Türkel Küçükmetin N, Ince U, Ciçek B, Akman H, Boztaş G, Tözün N. 2014. Isolated hepatic tuberculosis: a rare cause of hepatic mass lesions. Turk J Gastroenterol 25:110–112. [PubMed]
328. Essop AR, Hodkinson JH, Posen J, Segal I, Macerollo P. 1983. Simultaneous hepatic tuberculosis, cirrhosis and hepatoma. A case report. S Afr Med J 64:1102–1104. [PubMed]
329. Cunningham D, Mills PR, Quigley EM, Patrick RS, Watkinson G, MacKenzie JF, Russell RI. 1982. Hepatic granulomas: experience over a 10-year period in the West of Scotland. Q J Med 51:162–170. [PubMed]
330. Anderson CS, Nicholls J, Rowland R, LaBrooy JT. 1988. Hepatic granulomas: a 15-year experience in the Royal Adelaide Hospital. Med J Aust 148:71–74. [PubMed]
331. Satti MB, al-Freihi H, Ibrahim EM, Abu-Melha A, al-Ghassab G, al-Idrissi HY, al-Sohaibani MO. 1990. Hepatic granuloma in Saudi Arabia: a clinicopathological study of 59 cases. Am J Gastroenterol 85:669–674. [PubMed]
332. McCluggage WG, Sloan JM. 1994. Hepatic granulomas in Northern Ireland: a thirteen year review. Histopathology 25:219–228. [PubMed]
333. Guglielmi V, Manghisi OG, Pirrelli M, Caruso ML. 1994. Granulomatous hepatitis in a hospital population in southern Italy. Pathologica 86:271–278. (In Italian.) [PubMed]
334. Mert A, Ozaras R, Bilir M, Tahan V, Cetinkaya A, Yirmibescik S, Ozbay G, Senturk H. 2001. The etiology of hepatic granulomas. J Clin Gastroenterol 32:275–276. [PubMed]
335. Onal IK, Ersoy O, Aydinli M, Yonem O, Harmanci O, Sokmensuer C, Bayraktar Y. 2008. Hepatic granuloma in Turkish adults: a report of 13 cases. Eur J Intern Med 19:527–530. [PubMed]
336. Martin-Blondel G, Camara B, Selves J, Robic MA, Thebault S, Bonnet D, Alric L. 2010. Etiology and outcome of liver granulomatosis: a retrospective study of 21 cases. Rev Med Interne 31:97–106. (In French.) [PubMed]
337. Geramizadeh B, Jahangiri R, Moradi E. 2011. Causes of hepatic granuloma: a 12-year single center experience from southern Iran. Arch Iran Med 14:288–289. [PubMed]
338. Sahin M, Yılmaz G, Arhan M, Sen I. 2014. Hepatic granulomas in Turkey: a 6-year clinicopathological study of 35 cases. Turk J Gastroenterol 25:524–528. [PubMed]
339. Hurst A, Maier HM, Lough SA. 1947. Studies of hepatic function in pulmonary tuberculosis. Am J Med Sci 214:431–435. [PubMed]
340. Galen RS, Weiner D, Hartman SA. 1950. Functional hepatic impairment in pulmonary tuberculosis. Dis Chest 17:524–531. [PubMed]
341. Irani SK, Dobbins WO III. 1979. Hepatic granulomas: review of 73 patients from one hospital and survey of the literature. J Clin Gastroenterol 1:131–143. [PubMed]
342. Mansukhani S, Shah I. 2012. Hepatic dysfunction in children with tuberculosis on treatment with antituberculous therapy. Ann Hepatol 11:96–99. [PubMed]
343. Chang YG, Chen PJ, Hung CC, Chen MY, Lai MY, Chen DS. 1999. Opportunistic hepatic infections in AIDS patients with fever of unknown origin. J Formos Med Assoc 98:5–10. [PubMed]
344. Chen SX, Zhou L, Chen YZ, Pan HQ, Tang SW. 2016. Incidence and outcome of anti-tuberculosis drug-induced hepatotoxicity in tuberculosis inpatients. Zhonghua Liu Xing Bing Xue Za Zhi 37:930–934. (In Chinese.) [PubMed]
345. Sun Q, Zhang Q, Gu J, Sun WW, Wang P, Bai C, Xiao HP, Sha W. 2016. Prevalence, risk factors, management, and treatment outcomes of first-line antituberculous drug-induced liver injury: a prospective cohort study. Pharmacoepidemiol Drug Saf 25:908–917. [PubMed]
346. Bliven-Sizemore EE, Sterling TR, Shang N, Benator D, Schwartzman K, Reves R, Drobeniuc J, Bock N, Villarino ME, TB Trials Consortium. 2015. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. Int J Tuberc Lung Dis 19:1039–1044, i–v. [PubMed]
347. Gu J, Tang SJ, Tan SY, Wu Q, Zhang X, Liu C-X, Gao X-S, Yuan B-D, Han L-J, Gao A-P, Wu M-Y, Huang L-H, Ma J, Xiao H-P. 2015. An open-label, randomized and multi-center clinical trial to evaluate the efficacy of Silibinin in preventing drug-induced liver injury. Int J Clin Exp Med 8:4320–4327. [PubMed]
348. Shu CC, Lee CH, Lee MC, Wang JY, Yu CJ, Lee LN. 2013. Hepatotoxicity due to first-line anti-tuberculosis drugs: a five-year experience in a Taiwan medical centre. Int J Tuberc Lung Dis 17:934–939. [PubMed]
349. Santos NP, Callegari-Jacques SM, Ribeiro Dos Santos AK, Silva CA, Vallinoto AC, Fernandes DC, de Carvalho DC, Santos SE, Hutz MH. 2013. N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients. Int J Tuberc Lung Dis 17:499–504. [PubMed]
350. Babalık A, Arda H, Bakırcı N, Ağca S, Oruç K, Kızıltaş S, Cetintaş G, Calışır HC. 2012. Management of and risk factors related to hepatotoxicity during tuberculosis treatment. Tuberk Toraks 60:136–144. [PubMed]
351. Ben Mahmoud L, Ghozzi H, Kamoun A, Hakim A, Hachicha H, Hammami S, Sahnoun Z, Zalila N, Makni H, Zeghal K. 2012. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis. Pathol Biol (Paris) 60:324–330. [PubMed]
352. Keshavjee S, Gelmanova IY, Shin SS, Mishustin SP, Andreev YG, Atwood S, Furin JJ, Miller A. 2012. Hepatotoxicity during treatment for multidrug-resistant tuberculosis: occurrence, management and outcome. Int J Tuberc Lung Dis 16:596–603. [PubMed]
353. Leiro-Fernandez V, Valverde D, Vázquez-Gallardo R, Botana-Rial M, Constenla L, Agúndez JA, Fernández-Villar A. 2011. N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians. Int J Tuberc Lung Dis 15:1403–1408. [PubMed]
354. Shang P, Xia Y, Liu F, Wang X, Yuan Y, Hu D, Tu D, Chen Y, Deng P, Cheng S, Zhou L, Ma Y, Zhu L, Gao W, Wang H, Chen D, Yang L, He P, Wu S, Tang S, Lv X, Shu Z, Zhang Y, Yang Z, Chen Y, Li N, Sun F, Li X, He Y, Garner P, Zhan S. 2011. Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. PLoS One 6:e21836. [PubMed]
355. Teixeira RL, Morato RG, Cabello PH, Muniz LM, Moreira AS, Kritski AL, Mello FC, Suffys PN, Miranda AB, Santos AR. 2011. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. Mem Inst Oswaldo Cruz 106:716–724. [PubMed]
356. Nakazono T, Tezuka N, Tagawa H, Takayanagi K, Sugita H, Takase A, Yamaguchi T, Shimao T. 2011. Liver dysfunction during treatment of latent tuberculosis infection. Kekkaku 86:51–55. (In Japanese.) [PubMed]
357. Bose PD, Sarma MP, Medhi S, Das BC, Husain SA, Kar P. 2011. Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis. J Gastroenterol Hepatol 26:312–318. [PubMed]
358. Khalili H, Fouladdel S, Sistanizad M, Hajiabdolbaghi M, Azizi E. 2011. Association of N-acetyltransferase-2 genotypes and anti-tuberculosis induced liver injury; first case-controlled study from Iran. Curr Drug Saf 6:17–22. [PubMed]
359. Baghaei P, Tabarsi P, Chitsaz E, Saleh M, Marjani M, Shemirani S, Pooramiri MV, Kazempour M, Farnia P, Fahimi F, Mansouri D, Masjedi M. 2010. Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to antituberculous agents in new tuberculosis cases. Am J Ther 17:17–22. [PubMed]
360. Tariq S, Khan TS, Malik S, Anwar MS, Rashid A. 2009. Frequency of anti-tuberculous therapy-induced hepatotoxicity in patients and their outcome. J Ayub Med Coll Abbottabad 21:50–52. [PubMed]
361. Pukenyte E, Lescure FX, Rey D, Rabaud C, Hoen B, Chavanet P, Laiskonis AP, Schmit JL, May T, Mouton Y, Yazdanpanah Y. 2007. Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-tuberculosis treatment. Int J Tuberc Lung Dis 11:78–84. [PubMed]
362. Cho HJ, Koh WJ, Ryu YJ, Ki CS, Nam MH, Kim JW, Lee SY. 2007. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinburgh) 87:551–556. [PubMed]
363. Xia YY, Zhan SY. 2007. Systematic review of anti-tuberculosis drug induced adverse reactions in China. Zhonghua Jie He He Hu Xi Za Zhi 30:419–423. (In Chinese.) [PubMed]
364. Breen RA, Miller RF, Gorsuch T, Smith CJ, Schwenk A, Holmes W, Ballinger J, Swaden L, Johnson MA, Cropley I, Lipman MC. 2006. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax 61:791–794. [PubMed]
365. Ito K, Hoshino H, Nakazono T, Masuyama H, Sugita H, Yoshiyama T, Kato S. 2006. Liver damage in treatment of latent tuberculous infection by isoniazid. Kekkaku 81:651–660. (In Japanese.) [PubMed]
366. Senaratne WV, Pinidiyapathirage MJ, Perera GA, Wickremasinghe AR. 2006. Anti-tuberculosis drug inducd hepatitis—a Sri Lankan experience. Ceylon Med J 51:9–14. [PubMed]
367. Tost JR, Vidal R, Caylà J, Díaz-Cabanela D, Jiménez A, Broquetas JM, Study Group for Severe Hepatotoxicity Due to Anti-tuberculosis Drugs. 2005. Severe hepatotoxicity due to anti-tuberculosis drugs in Spain. Int J Tuberc Lung Dis 9:534–540. [PubMed]
368. Sharifzadeh M, Rasoulinejad M, Valipour F, Nouraie M, Vaziri S. 2005. Evaluation of patient-related factors associated with causality, preventability and severity of hepatotoxicity during antituberculosis treatment. Pharmacol Res 51:353–358. [PubMed]
369. McElroy PD, Ijaz K, Lambert LA, Jereb JA, Iademarco MF, Castro KG, Navin TR. 2005. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis 41:1125–1133. [PubMed]
370. Fountain FF, Tolley E, Chrisman CR, Self TH. 2005. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 128:116–123. [PubMed]
371. van Hest R, Baars H, Kik S, van Gerven P, Trompenaars MC, Kalisvaart N, Keizer S, Borgdorff M, Mensen M, Cobelens F. 2004. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. Clin Infect Dis 39:488–496. [PubMed]
372. Fernández-Villar A, Sopeña B, Fernández-Villar J, Vázquez-Gallardo R, Ulloa F, Leiro V, Mosteiro M, Piñeiro L. 2004. The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 8:1499–1505. [PubMed]
373. Shakya R, Rao BS, Shrestha B. 2004. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann Pharmacother 38:1074–1079. [PubMed]
374. Teleman MD, Chee CB, Earnest A, Wang YT. 2002. Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore. Int J Tuberc Lung Dis 6:699–705. [PubMed]
375. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. 2002. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 166:916–919. [PubMed]
376. Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, Maekura R, Ito M, Yamamoto Y, Ogura T, Maeda K, Komuta K, Igarashi T, Azuma J. 2000. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 4:256–261. [PubMed]
377. Hwang SJ, Wu JC, Lee CN, Yen FS, Lu CL, Lin TP, Lee SD. 1997. A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol 12:87–91. [PubMed]
378. Døssing M, Wilcke JT, Askgaard DS, Nybo B. 1996. Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis 77:335–340. [PubMed]
379. Ormerod LP, Horsfield N. 1996. Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tuber Lung Dis 77:37–42. [PubMed]
380. Schaberg T, Rebhan K, Lode H. 1996. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 9:2026–2030. [PubMed]
381. Vidal Pla R, de Gracia X, Gallego B, Algueró C, Bravo C. 1991. The hepatotoxicity of tuberculosis treatment. Med Clin (Barcelona) 97:481–485. (In Spanish.) [PubMed]
382. Musch E, Eichelbaum M, Wang JK, von Sassen W, Castro-Parra M, Dengler HJ. 1982. Incidence of hepatotoxic side effects during antituberculous therapy (INH, RMP, EMB) in relation to the acetylator phenotype (author’s translation). Klin Wochenschr 60:513–519. (In German.) [PubMed]
383. Byrd RB, Horn BR, Griggs GA, Solomon DA. 1977. Isoniazid chemoprophylaxis. Association with detection and incidence of liver toxicity. Arch Intern Med 137:1130–1133. [PubMed]
384. Rossouw JE, Saunders SJ. 1975. Hepatic complications of antituberculous therapy. Q J Med 44:1–16. [PubMed]
microbiolspec.TNMI7-0025-2016.citations
cm/5/1
content/journal/microbiolspec/10.1128/microbiolspec.TNMI7-0025-2016
Loading

Citations loading...

Loading

Article metrics loading...

/content/journal/microbiolspec/10.1128/microbiolspec.TNMI7-0025-2016
2017-02-24
2017-04-25

Abstract:

Tuberculosis of the liver, biliary tract, and pancreas is discussed. In addition, tuberculosis in the setting of HIV-AIDS and liver transplantation is explored. Drug-induced liver injury secondary to antituberculosis medication and monitoring and prophylactic treatment for such injury is also considered.

Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of FIGURE 1
FIGURE 1

Tubercle comprising Langerhans giant cells, epithelioid cells, and lymphocytes. Reprinted from reference 81 , with permission.

Source: microbiolspec February 2017 vol. 5 no. 1 doi:10.1128/microbiolspec.TNMI7-0025-2016
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 2
FIGURE 2

Low-magnification hematoxylin-and-eosin-stained hepatic granuloma with giant cells. © University of Alabama at Birmingham, Department of Pathology for the PIER images.

Source: microbiolspec February 2017 vol. 5 no. 1 doi:10.1128/microbiolspec.TNMI7-0025-2016
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 3
FIGURE 3

Hypodense 13.0- by 8.0- by 7.0-cm hepatic tuberculoma with calcification. Reprinted from reference 81 , with permission.

Source: microbiolspec February 2017 vol. 5 no. 1 doi:10.1128/microbiolspec.TNMI7-0025-2016
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 4
FIGURE 4

Miliary tuberculosis of the liver. © University of Alabama at Birmingham, Department of Pathology for the PIER images.

Source: microbiolspec February 2017 vol. 5 no. 1 doi:10.1128/microbiolspec.TNMI7-0025-2016
Permissions and Reprints Request Permissions
Download as Powerpoint

Tables

Generic image for table
TABLE 1

Histopathologic spectrum of hepatobiliary tuberculosis

Source: microbiolspec February 2017 vol. 5 no. 1 doi:10.1128/microbiolspec.TNMI7-0025-2016
Generic image for table
TABLE 2

Biopsy incidence of hepatic granulomas in pulmonary tuberculosis

Source: microbiolspec February 2017 vol. 5 no. 1 doi:10.1128/microbiolspec.TNMI7-0025-2016
Generic image for table
TABLE 3

Biopsy incidence of hepatic granulomas in extrapulmonary, localized hepatic, and miliary tuberculosis

Source: microbiolspec February 2017 vol. 5 no. 1 doi:10.1128/microbiolspec.TNMI7-0025-2016
Generic image for table
TABLE 4

Demonstration of hepatic AFB in pulmonary tuberculosis

Source: microbiolspec February 2017 vol. 5 no. 1 doi:10.1128/microbiolspec.TNMI7-0025-2016
Generic image for table
TABLE 5

Caseating granulomas in hepatic biopsy material in localized hepatic and miliary tuberculosis

Source: microbiolspec February 2017 vol. 5 no. 1 doi:10.1128/microbiolspec.TNMI7-0025-2016
Generic image for table
TABLE 6

Nonspecific hepatic lesions in pulmonary tuberculosis

Source: microbiolspec February 2017 vol. 5 no. 1 doi:10.1128/microbiolspec.TNMI7-0025-2016
Generic image for table
TABLE 7

Tuberculosis as a cause of hepatic granulomas

Source: microbiolspec February 2017 vol. 5 no. 1 doi:10.1128/microbiolspec.TNMI7-0025-2016
Generic image for table
TABLE 8

Hepatic function tests and biochemical abnormalities in tuberculosis

Source: microbiolspec February 2017 vol. 5 no. 1 doi:10.1128/microbiolspec.TNMI7-0025-2016
Generic image for table
TABLE 9

Characteristics of pancreatic tuberculosis as reported in studies involving 10 or more patients in the medical literature from 1966 to 2016

Source: microbiolspec February 2017 vol. 5 no. 1 doi:10.1128/microbiolspec.TNMI7-0025-2016
Generic image for table
TABLE 10

Hepatic in AIDS

Source: microbiolspec February 2017 vol. 5 no. 1 doi:10.1128/microbiolspec.TNMI7-0025-2016
Generic image for table
TABLE 11

Incidence of TB-DILI

Source: microbiolspec February 2017 vol. 5 no. 1 doi:10.1128/microbiolspec.TNMI7-0025-2016

Supplemental Material

No supplementary material available for this content.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error